SPC107
Daklatasvír og lyfjafræðilega hæf sölt þar af, sérstaklega daklatasvírdíhýdróklóríð
Status:
AfskrifuðApplication date:
27.1.2015Application published:
15.2.2015Grant published:
15.4.2016
Max expiry date:
25.8.2029Medicine name:
DaklinzaMedicine for children:
No
Timeline
Today
27.1.2015Application
15.2.2015Publication
15.4.2016Registration
25.8.2029Expires
Marketing license
IS authorization number:
EU/1/14/939/001-002; EU/1/14/939/003-004Date:
11.9.2014
Foreign authorization number:
EU/1/14/939/001-004Date:
22.8.2014
Owner
Name:
Bristol-Myers Squibb Holdings Ireland Unlimited CompanyAddress:
Hinterbergstrasse 16, Steinhausen CH
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2049522